表紙
市場調查報告書

下一代癌症診斷:技術和全球市場

Next Generation Cancer Diagnostics: Technologies and Global Markets

出版商 BCC Research 商品編碼 953891
出版日期 內容資訊 英文 318 Pages
訂單完成後即時交付
價格
下一代癌症診斷:技術和全球市場 Next Generation Cancer Diagnostics: Technologies and Global Markets
出版日期: 2020年08月11日內容資訊: 英文 318 Pages
簡介

全球下一代癌症診斷市場的規模預計將從2020年的62億美元增長到2025年的167億美元,預計從2020年到2025年的複合年增長率為21.9%。它是下一代胃腸道癌診斷市場規模預計將從2020年的15億美元增長到2025年的45億美元,預計到2020年至2025年的複合年增長率為24.5%。我是。下一代乳腺癌的癌症診斷市場規模預計將從2020年的16億美元增長到2025年的31億美元,2020年至2025年的複合年增長率為13.9% 。

該報告調查了全球下一代癌症診斷市場,市場概況,市場規模數據和CAGR預測,全球市場趨勢分析,主要舉措和計劃,按技術和癌症站點進行的分析,以及主要公司的資料。

第1章簡介

  • 研究目的
  • 調查原因
  • 報告範圍
  • 信息來源
  • 調查方法
  • 地理細分
  • 分析師職業
  • BCC海關調查
  • BCC研究相關報告

第2章摘要和重點

第3章概述

  • 大型計劃和財團
  • 市場規模
  • 液體活檢成為市場驅動力
  • 主要趨勢
  • 行業

第4章技術

  • 診斷概述
  • 陣列和微流體(LOAC)技術
  • DNA微陣列
  • 蛋白質微陣列
  • 微流體
  • 多重傳統技術
  • 下一代測序技術
  • 聚合□鏈反應(PCR)技術

第5章液體活檢技術

  • 液體活檢生物標誌物
  • 癌症基因組學
  • 循環腫瘤細胞技術
  • CTC工作流程
  • 細胞分離技術
  • CTC樣品預處理技術
  • CTC下游分析技術
  • 液體活檢與常規活檢的比較
  • 癌症測試
  • 以頭像為主導的診斷□□方法

第6章下一代癌症診斷:主要舉措和計劃

  • Blood Profiling Atlas
  • Cancer-ID
  • Cancer Moon Shots
  • China Precision Medicine Initiative
  • ClinGen
  • CTC Trap Consortium
  • Early Cancer Detection Consortium
  • EpiFemCare
  • France Genomic Medicine Plan
  • Friends of Cancer Research Project
  • Human Cell Atlas
  • Immunomonitor Consortium
  • Integration of Imaging and Fluid-Based Tumor Monitoring
  • Liquid Biopsies and Imaging for Improved Cancer Care
  • Million Veteran Program
  • MedSeq
  • Next-Generation Single-Cell Analysis Program
  • Population Sequencing Projects
  • Precancer Atlas
  • Precision Medicine Initiative
  • Prompt
  • QuIP Project
  • Single-Cell Proteomics and Lipidomics Project
  • TopMed
  • Treehouse Childhood Cancer Initiative
  • Very Rare Cancer Consortium
  • Worldwide Innovative Networking (WIN) Consortium
  • Single-Cell Research
  • Cambridge Single-Cell Analysis Core Facility
  • Harvard Medical School Single-Cell Core
  • Mayo Medical Genome Facility
  • National Center for Single-Cell Biology
  • Single-Cell Analysis Core
  • UC San Francisco Single-Cell Analysis Center
  • Population Sequencing Programs

第7章下一代癌症診斷應用程序:按癌症部位劃分

  • 簡介
  • 膀胱癌
  • 腦癌
  • 乳腺癌
  • 乳腺癌篩查
  • 預後和藥物遺傳學測試
  • 乳腺癌MDx平台
  • 下一代乳腺癌測試狀態
  • 早期發現乳腺癌並進行篩查測試
  • 乳腺癌風險測試
  • 化療,復發概率,對亞型的反應
  • 婦科癌症
  • 宮頸癌
  • 卵巢癌
  • 大腸癌
  • 常規結腸癌篩查測試
  • 下一代大腸癌診斷測試
  • 來源不明的癌症
  • 胃癌
  • 腎臟癌
  • 血液檢查:白血病和骨髓瘤
  • 肝癌
  • 肺癌
  • 血液檢查:淋巴瘤
  • 黑色素瘤
  • 泛癌
  • 前列腺癌
  • 甲狀腺癌

第8章癌症診斷行業

  • 順序設備行業
  • 長測序行業
  • 測序信息產業
  • PCR行業
  • 液滴數字PCR行業
  • 四氯化碳捕獲和檢測行業
  • 液體活檢分析行業

第9章行業收購與戰略聯盟

  • 收購
  • 戰略聯盟

第10章癌症診斷市場

  • 推動增長的力量
  • COVID-19對癌症診斷市場的影響
  • 癌症市場
  • 下一代癌症診斷市場:按癌症站點劃分
  • 膀胱癌
  • 腦癌
  • 乳腺癌
  • 大腸癌
  • 婦科癌症
  • 來源不明的癌症
  • 胃癌
  • 血液癌
  • 腎臟癌
  • 肝癌
  • 肺癌
  • 黑色素瘤
  • 泛癌
  • 胰腺癌
  • 前列腺癌
  • 甲狀腺癌
  • 按分析目的的下一代癌症診斷市場
  • 篩查/早期檢測市場
  • 診斷市場
  • 治療指導市場
  • 監控市場
  • 通過測試平台的下一代癌症診斷市場
  • PCR測試平台
  • NGS測試平台
  • 陣列/微流體測試平台
  • 電池和/或電動汽車捕獲測試平台
  • 多重傳統測試平台
  • 測試平台市場:癌症網站
  • PCR測試平台
  • NGS測試平台
  • 按診斷細分市場
  • 篩查/早期檢測市場
  • 診斷市場
  • 監控市場
  • 治療指導市場
  • 乳腺癌診斷
  • 大腸癌的診斷
  • 肺癌診斷
  • 泛癌診斷
  • 前列腺癌的診斷
  • 區域市場分析

第11章專利

  • 循環腫瘤細胞專利
  • 外來體專利
  • 無細胞DNA(cfDNA)專利
  • 與生物標誌物有關的專利
  • 專利注意事項:AI在癌症診斷中

第12章公司簡介

  • 20/20 GENE SYSTEMS
  • ABBOTT LABORATORIES
  • ADAPTIVE BIOTECHNOLOGIES INC.
  • AGENDIA NV
  • AGILENT TECHNOLOGIES INC.
  • AKADEUM LIFE SCIENCES
  • AMBRY GENETICS
  • AMOY DIAGNOSTICS CO. LTD.
  • ANGLE PLC
  • APOCELL INC.
  • APOSTLE INC.
  • ARBOR VITA CORP.
  • ARCHER DX
  • AROCELL AB
  • ARUP LABORATORIES
  • ASPIRA LABS
  • ASURAGEN, INC.
  • ATILA BIOSYSTEMS
  • AVIVA BIOSCIENCES
  • BECTON, DICKINSON AND CO.
  • BGI SHENZHEN
  • BIOCARTIS NV
  • BIOCEPT INC.
  • BIODESIX INC.
  • BIOFIDELITY LTD.
  • BIOFLUIDICA INC.
  • BIOLIDICS LTD.
  • BIOLOGICAL DYNAMICS INC.
  • BIOPROGNOS SL
  • BIOTHERANOSTICS INC.
  • BIO-TECHNE CORP.
  • BLUESTAR GENOMICS INC.
  • CANCER GENETICS INC.
  • CARIS LIFE SCIENCES
  • CASTLE BIOSCIENCES INC.
  • CC DIAGNOSTICS BV
  • CELCUITY INC.
  • CELLMAX LIFE
  • CELLULAR ANALYTICS
  • CELL MICROSYSTEMS INC.
  • CELSEE DIAGNOSTICS
  • CHIP DIAGNOSTICS
  • CHRONIX BIOMEDICAL
  • CIRCULOGENE THERANOSTICS
  • CLINICAL GENOMICS TECHNOLOGIES
  • CODIAK BIOSCIENCES
  • DANAHER CORP.
  • DECIPHER BIOSCIENCES
  • DERMTECH
  • DIACARTA INC.
  • DNALYTICS
  • EPIGENOMICS AG
  • EPIC SCIENCES INC.
  • EXACT SCIENCES CORP.
  • FLUXION BIOSCIENCES INC.
  • FREENOME INC.
  • FULGENT GENETICS INC.
  • GENECENTRIC THERAPEUTICS
  • GENEDX INC.
  • GENERA BIOSYSTEMS
  • GENESEQ BIOSCIENCES PTY LTD.
  • GENETRON HEALTH TECHNOLOGIES INC.
  • GENEOSCOPY LLC
  • GENEXOSOME TECHNOLOGIES INC.
  • GRAIL INC.
  • GUARDANT HEALTH INC.
  • HOLOGIC INC.
  • HTG MOLECULAR DIAGNOSTICS INC.
  • IDL BIOTECH
  • ILLUMINA INC.
  • IMMUNIS AI
  • INCELLDX INC.
  • INIVATA LTD.
  • INTERPACE BIOSCIENCES INC.
  • INVITAE INC.
  • INVIVOSCRIBE INC.
  • JBS SCIENCE INC.
  • LABORATORY CORP. OF AMERICA INC.
  • LEXENT BIO INC.
  • LUCENCE DIAGNOSTICS PTE. LTD.
  • LUNGLIFE AI, INC.
  • MDNA LIFE SCIENCES INC.
  • MDXHEALTH INC.
  • MEDGENOME INC.
  • MENARINI SILICON BIOSYSTEMS SPA
  • MIRADX
  • MIR SCIENTIFIC
  • MUTANTDX
  • MY PERSONAL THERAPEUTICS LTD.
  • MYRIAD GENETICS INC.
  • NEOGENOMICS LABORATORIES
  • NEO NEW ONCOLOGY GMBH
  • NODEXUS
  • NOVIGENIX SA
  • NRICH DX
  • NUCLEIX
  • NUPROBE INC.
  • ONCIMMUNE HOLDINGS PLC
  • ONCOCYTE CORP.
  • ONCODNA S.A.
  • OPKO HEALTH
  • OXFORD GENE TECHNOLOGY
  • PACIFIC EDGE LTD.
  • PANGAEA LABORATORY
  • PANGAEA ONCOLOGY
  • PERSONAL GENOME DIAGNOSTICS INC.
  • POLYMEDCO, INC.
  • PREDICINE INC.
  • PROVISTA DIAGNOSTICS INC.
  • QIAGEN NV
  • QUANTUMDX
  • QUEST DIAGNOSTICS INC.
  • RARECYTE INC.
  • RESOLUTION BIOSCIENCE INC.
  • ROCHE HOLDING AG
  • SAGA DIAGNOSTICS AB
  • SANOMICS LTD.
  • SIENNA CANCER DIAGNOSTICS LTD.
  • SINGLERA GENOMICS INC.
  • SISTEMAS GENOMICOS
  • SKYLINEDX BV
  • STAGE ZERO LIFE SCIENCES
  • STRAND LIFE SCIENCES PVT., LTD.
  • SYSMEX INOSTICS GMBH
  • THERMO FISHER SCIENTIFIC INC.
  • THRIVE EARLIER DETECTION CORP.
  • TIZIANA LIFE SCIENCES PLC
  • VORTEX BIOSCIENCES
  • VERACYTE
  • VOLITIONRX
  • XING TECHNOLOGIES LLC
  • YIKON GENOMICS CO. LTD.
目錄
Product Code: BIO081C

Highlights:

The global market for next generation cancer diagnostics is expected to grow from $6.2 billion in 2020 to $16.7 billion by 2025 with a compound annual growth rate (CAGR) of 21.9% for the period of 2020-2025.

Next generation digestive systems cancer diagnostics market is expected to grow from $1.5 billion in 2020 to $4.5 billion by 2025 with a compound annual growth rate (CAGR) of 24.5% for the period of 2020-2025.

Next generation breast cancer diagnostics market is expected to grow from $1.6 billion in 2020 to $3.1 billion by 2025 with a compound annual growth rate (CAGR) of 13.9% for the period of 2020-2025.

Report Scope:

The scope of this report includes next generation diagnostic technologies, applications, industry subsegments, major funding initiatives, patents and companies. The market sizes for next generation cancer diagnostics are given for 2019, 2020 (estimated) and 2025 (forecasted).

This report reviews the main next generation diagnostic technologies, including next generation sequencing (NGS), polymerase chain reaction (PCR), multiplex conventional, cell or extracellular vesicle capture and arrays/microfluidics. The report also discusses, in-depth, various liquid biopsy platforms and how these compare with tissue-based testing.

The report discusses several significant, large-scale research initiatives that contribute to cancer diagnostic development. Key forces driving the market are enumerated.

The structures of several important industry subsectors are reviewed, as well as major industry acquisitions and strategic alliances from Jan. 2019 through June 2020. The industry subsectors analyzed include DNA sequencing instruments, long-read DNA sequencing, informatics, PCR, droplet digital PCR, CTC capture and detection and liquid biopsy.

The market for next generation cancer diagnostics is analyzed in depth. The market is analyzed by cancer site (bladder, brain, breast, colorectal, cancer of unknown primary, gastric, gynecologic, hematologic, kidney, liver, lung, pan-cancer, pancreatic, prostate, melanoma and thyroid), by test purpose (screening/early detection, diagnosis, monitoring, therapy guidance), by test platform (arrays/microfluidics, cell/EV capture, multiplex conventional, PCR and NGS) and by geography (North America, Europe, Asia Pacific, Rest of World).

Market data covers 2019, 2020 (estimated) and 2025 (forecasted).

There is a special section discussing the impact of COVID-19 on the market for next generation cancer diagnostics.

More than 130 companies in the next generation cancer diagnostics industry are profiled in this report.

BCC Research provides a summary of the main industry acquisitions and strategic alliances from Jan. 2019 through June 2020, including key alliance trends.

Report Includes:

  • 22 data tables and 74 additional tables
  • An overview of the global market and technologies for next generation cancer diagnostics
  • Analyses of global market trends, with data from 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025
  • Analyses of the next generation cancer diagnostics market by cancer site, analysis purpose, analysis platform and region
  • Discussion on arrays and microfluidics (LOAC) technologies, multiplex conventional technologies, next generation sequencing technology and polymerase chain reaction (PCR) technology
  • Evaluation of current market trends, market size, market forecast, pipeline analysis of new products, and regulatory scenarios of the cancer diagnostics market
  • Discussion on factors affecting the market including cancer diagnostics needs, regulatory trends, industry structure, and patent statuses
  • Details of the key initiatives and programs related to the next generation cancer diagnostics market
  • Market share analysis of the key companies of the industry, their strategic profiling, competitive landscape, and their detailed company profiles, including Abbott Laboratories, Illumina Inc., Myriad Genetics Inc., Qiagen NV, Oche Holding AG, and Thermo Fisher Scientific Inc.

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Overview

  • Large-Scale Initiatives and Consortia
  • Market Size
  • Liquid Biopsy as a Market Driving Force
  • Key Trends
  • Industry

Chapter 4 Technologies

  • Diagnostics Overview
  • Arrays and Microfluidics (LOAC) Technologies
  • DNA Microarrays
  • Protein Microarrays
  • Microfluidics
  • Multiplex Conventional Technologies
  • Next Generation Sequencing Technology
  • Polymerase Chain Reaction (PCR) Technology

Chapter 5 Liquid Biopsy Technologies

  • Liquid Biopsy Biomarkers
  • Cancer Genomics
  • Circulating Tumor Cell Technologies
  • CTC Workflow
  • Cell Isolation Technologies
  • CTC Sample Preparation Technologies
  • CTC Downstream Analysis Technologies
  • Comparison of Liquid Biopsy with Conventional Biopsy
  • Cancer Testing
  • Avatar-Driven Diagnostic Approaches

Chapter 6 Next Generation Cancer Diagnostics: Key Initiatives and Programs

  • Blood Profiling Atlas
  • Cancer-ID
  • Cancer Moon Shots
  • China Precision Medicine Initiative
  • ClinGen
  • CTC Trap Consortium
  • Early Cancer Detection Consortium
  • EpiFemCare
  • France Genomic Medicine Plan
  • Friends of Cancer Research Project
  • Human Cell Atlas
  • Immunomonitor Consortium
  • Integration of Imaging and Fluid-Based Tumor Monitoring
  • Liquid Biopsies and Imaging for Improved Cancer Care
  • Million Veteran Program
  • MedSeq
  • Next-Generation Single-Cell Analysis Program
  • Population Sequencing Projects
  • Precancer Atlas
  • Precision Medicine Initiative
  • Prompt
  • QuIP Project
  • Single-Cell Proteomics and Lipidomics Project
  • TopMed
  • Treehouse Childhood Cancer Initiative
  • Very Rare Cancer Consortium
  • Worldwide Innovative Networking (WIN) Consortium
  • Single-Cell Research
  • Cambridge Single-Cell Analysis Core Facility
  • Harvard Medical School Single-Cell Core
  • Mayo Medical Genome Facility
  • National Center for Single-Cell Biology
  • Single-Cell Analysis Core
  • UC San Francisco Single-Cell Analysis Center
  • Population Sequencing Programs

Chapter 7 Next Generation Cancer Diagnostic Applications by Cancer Site

  • Introduction
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Breast Cancer Screening
  • Prognosis and Pharmacogenetics Tests
  • Breast Cancer MDx Platforms
  • Status of Next Generation Breast Cancer Tests
  • Breast Cancer Early Detection and Screening Tests
  • Breast Cancer Risk Tests
  • Response to Chemotherapy, Recurrence Probability and Subtyping
  • Gynecologic Cancers
  • Cervical Cancer
  • Ovarian Cancer
  • Colorectal Cancer
  • Conventional Colorectal Cancer Screening Tests
  • Next Generation Colorectal Cancer Diagnostic Tests
  • Cancer Unknown Primary
  • Gastric Cancer
  • Kidney Cancer
  • Hematologic Tests: Leukemia and Myeloma
  • Liver Cancer
  • Lung Cancer
  • Hematologic Tests: Lymphomas
  • Melanoma
  • Pan-Cancer
  • Prostate Cancer
  • Thyroid Cancer

Chapter 8 Cancer Diagnostics Industries

  • Sequencing Instruments Industry
  • Long Read Sequencing Industry
  • Sequencing Informatics Industry
  • PCR Industry
  • Droplet Digital PCR Industry
  • CTC Capture and Detection Industry
  • Liquid Biopsy Assay Industry

Chapter 9 Industry Acquisitions and Strategic Alliances

  • Acquisitions
  • Strategic Alliances

Chapter 10 Cancer Diagnostics Markets

  • Forces Driving Growth
  • COVID-19 Impact on Cancer Diagnostic Markets
  • Cancer Markets
  • Market for Next Generation Cancer Diagnostics by Cancer Site
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Gynecologic Cancers
  • Cancer of Unknown Primary
  • Gastric Cancer
  • Hematologic Cancers
  • Kidney Cancer
  • Liver Cancer
  • Lung Cancer
  • Melanoma
  • Pan-Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Thyroid Cancer
  • Market for Next Generation Cancer Diagnostics by Purpose of Analysis
  • Screening/Early Detection Market
  • Diagnosis Market
  • Therapy Guidance Market
  • Monitoring Market
  • Market for Next Generation Cancer Diagnostics by Test Platform
  • PCR Test Platform
  • NGS Test Platform
  • Array/Microfluidics Test Platform
  • Cells and/or EV Capture Test Platform
  • Multiplex Conventional Test Platform
  • Market for Test Platforms by Cancer Site
  • PCR Test Platform
  • NGS Test Platform
  • Market by Diagnostic Segment
  • Screening/Early Detection Market
  • Diagnostics Market
  • Monitoring Market
  • Therapy Guidance Market
  • Breast Cancer Diagnostics
  • Colorectal Cancer Diagnostics
  • Lung Cancer Diagnostics
  • Pan-Cancer Diagnostics
  • Prostate Cancer Diagnostics
  • Regional Market Analysis

Chapter 11 Patents

  • Circulating Tumor Cell Patents
  • Exosome Patents
  • Cell-free DNA (cfDNA) Patents
  • Biomarker-Related Patents
  • Patent Considerations: AI in Cancer Diagnostics

Chapter 12 Company Profiles

  • 20/20 GENE SYSTEMS
  • ABBOTT LABORATORIES
  • ADAPTIVE BIOTECHNOLOGIES INC.
  • AGENDIA NV
  • AGILENT TECHNOLOGIES INC.
  • AKADEUM LIFE SCIENCES
  • AMBRY GENETICS
  • AMOY DIAGNOSTICS CO. LTD.
  • ANGLE PLC
  • APOCELL INC.
  • APOSTLE INC.
  • ARBOR VITA CORP.
  • ARCHER DX
  • AROCELL AB
  • ARUP LABORATORIES
  • ASPIRA LABS
  • ASURAGEN, INC.
  • ATILA BIOSYSTEMS
  • AVIVA BIOSCIENCES
  • BECTON, DICKINSON AND CO.
  • BGI SHENZHEN
  • BIOCARTIS NV
  • BIOCEPT INC.
  • BIODESIX INC.
  • BIOFIDELITY LTD.
  • BIOFLUIDICA INC.
  • BIOLIDICS LTD.
  • BIOLOGICAL DYNAMICS INC.
  • BIOPROGNOS SL
  • BIOTHERANOSTICS INC.
  • BIO-TECHNE CORP.
  • BLUESTAR GENOMICS INC.
  • CANCER GENETICS INC.
  • CARIS LIFE SCIENCES
  • CASTLE BIOSCIENCES INC.
  • CC DIAGNOSTICS BV
  • CELCUITY INC.
  • CELLMAX LIFE
  • CELLULAR ANALYTICS
  • CELL MICROSYSTEMS INC.
  • CELSEE DIAGNOSTICS
  • CHIP DIAGNOSTICS
  • CHRONIX BIOMEDICAL
  • CIRCULOGENE THERANOSTICS
  • CLINICAL GENOMICS TECHNOLOGIES
  • CODIAK BIOSCIENCES
  • DANAHER CORP.
  • DECIPHER BIOSCIENCES
  • DERMTECH
  • DIACARTA INC.
  • DNALYTICS
  • EPIGENOMICS AG
  • EPIC SCIENCES INC.
  • EXACT SCIENCES CORP.
  • FLUXION BIOSCIENCES INC.
  • FREENOME INC.
  • FULGENT GENETICS INC.
  • GENECENTRIC THERAPEUTICS
  • GENEDX INC.
  • GENERA BIOSYSTEMS
  • GENESEQ BIOSCIENCES PTY LTD.
  • GENETRON HEALTH TECHNOLOGIES INC.
  • GENEOSCOPY LLC
  • GENEXOSOME TECHNOLOGIES INC.
  • GRAIL INC.
  • GUARDANT HEALTH INC.
  • HOLOGIC INC.
  • HTG MOLECULAR DIAGNOSTICS INC.
  • IDL BIOTECH
  • ILLUMINA INC.
  • IMMUNIS AI
  • INCELLDX INC.
  • INIVATA LTD.
  • INTERPACE BIOSCIENCES INC.
  • INVITAE INC.
  • INVIVOSCRIBE INC.
  • JBS SCIENCE INC.
  • LABORATORY CORP. OF AMERICA INC.
  • LEXENT BIO INC.
  • LUCENCE DIAGNOSTICS PTE. LTD.
  • LUNGLIFE AI, INC.
  • MDNA LIFE SCIENCES INC.
  • MDXHEALTH INC.
  • MEDGENOME INC.
  • MENARINI SILICON BIOSYSTEMS SPA
  • MIRADX
  • MIR SCIENTIFIC
  • MUTANTDX
  • MY PERSONAL THERAPEUTICS LTD.
  • MYRIAD GENETICS INC.
  • NEOGENOMICS LABORATORIES
  • NEO NEW ONCOLOGY GMBH
  • NODEXUS
  • NOVIGENIX SA
  • NRICH DX
  • NUCLEIX
  • NUPROBE INC.
  • ONCIMMUNE HOLDINGS PLC
  • ONCOCYTE CORP.
  • ONCODNA S.A.
  • OPKO HEALTH
  • OXFORD GENE TECHNOLOGY
  • PACIFIC EDGE LTD.
  • PANGAEA LABORATORY
  • PANGAEA ONCOLOGY
  • PERSONAL GENOME DIAGNOSTICS INC.
  • POLYMEDCO, INC.
  • PREDICINE INC.
  • PROVISTA DIAGNOSTICS INC.
  • QIAGEN NV
  • QUANTUMDX
  • QUEST DIAGNOSTICS INC.
  • RARECYTE INC.
  • RESOLUTION BIOSCIENCE INC.
  • ROCHE HOLDING AG
  • SAGA DIAGNOSTICS AB
  • SANOMICS LTD.
  • SIENNA CANCER DIAGNOSTICS LTD.
  • SINGLERA GENOMICS INC.
  • SISTEMAS GENOMICOS
  • SKYLINEDX BV
  • STAGE ZERO LIFE SCIENCES
  • STRAND LIFE SCIENCES PVT., LTD.
  • SYSMEX INOSTICS GMBH
  • THERMO FISHER SCIENTIFIC INC.
  • THRIVE EARLIER DETECTION CORP.
  • TIZIANA LIFE SCIENCES PLC
  • VORTEX BIOSCIENCES
  • VERACYTE
  • VOLITIONRX
  • XING TECHNOLOGIES LLC
  • YIKON GENOMICS CO. LTD.

List of Tables

  • Summary Table: Global Market for Next Generation Cancer Diagnostics, by Cancer Site, Through 2025
    • Table 1: Next Generation Cancer Diagnostics: Scope of Report
    • Table 2: Large-Scale Initiatives: Cancer Diagnostics Industry
    • Table 3: Global Market for Next Generation Cancer Diagnostics, by Technology Platform, Through 2025
    • Table 4: Key Trends in the Market for Next Generation Cancer Diagnostics
    • Table 5: Next Generation Cancer Diagnostics Industry Subsectors
    • Table 6: Diagnostic Market Segments
    • Table 7: Next Generation Diagnostics: Key Analysis Platforms
    • Table 8: Analysis Platforms and Biomarker Types
    • Table 9: DNA Microarray Technologies in Cancer Diagnostics
    • Table 10: Design Features of Protein Microarray Technologies
    • Table 11: Microfluidic LOAC Types Used in Cancer Diagnostics
    • Table 12: Advanced Sequencing Technologies
    • Table 13: Illumina Next Generation Sequencing Workflow
    • Table 14: Thermo Fisher Scientific's Next Generation Sequencing Workflow
    • Table 15: Main Ingredients of PCR Technology
    • Table 16: PCR Process
    • Table 17: Advantages of Droplet Digital PCR for Single-Cell Analysis
    • Table 18: Liquid Biopsy Biomarker Classes
    • Table 19: Cancer Genomic Sequencing and Liquid Biopsy
    • Table 20: Single-Cell Analysis to Identify Cancer Driver Mutations
    • Table 21: Genomics-Based Oncology Workflow
    • Table 22: Unique Challenges: CTC Capture and Analysis
    • Table 23: CTC Workflow
    • Table 24: Cell Differentiators
    • Table 25: Cell Isolation Technologies
    • Table 26: CTC Sample Preparation Technologies
    • Table 27: Single-Cell Analysis Technologies
    • Table 28: Estimated Annual Solid Biopsy Procedures, U.S., Selected Cancers
    • Table 29: Main Risks of Needle-Based Tissue Biopsies
    • Table 30: Factors in Tissue Biopsy
    • Table 31: Approaches to Avatar-Driven Cancer Diagnostics
    • Table 32: R&D: Next Generation Cancer Diagnostics
    • Table 33: Single-Cell Core Research Facilities
    • Table 34: Population Sequencing Projects
    • Table 35: Bladder Cancer Diagnostic Tests, 2020
    • Table 36: Brain Cancer: Next Generation Diagnostics Tests, 2020
    • Table 37: Annual Breast Cancer Treatment Decisions, U.S., by Cancer Classification, 2020
    • Table 38: Breast Cancer MDx Technology Platforms, 2020
    • Table 39: Next Generation Breast Cancer Tests, 2020
    • Table 40: Next Generation Human Papilloma Virus and Cervical Cancer Screening and Genotyping Tests, 2020
    • Table 41: Ovarian Cancer Early Screening Formats, 2020
    • Table 42: Ovarian Cancer: Next Generation Diagnostics Tests, 2020
    • Table 43: CRC Screening Tests, 2020
    • Table 44: Colorectal Cancer: Next Generation Diagnostic Tests, 2020
    • Table 45: Cancer Unknown Primary: Next Generation Diagnostic Tests, 2020
    • Table 46: Gastric Cancer: Next Generation Diagnostic Tests, 2020
    • Table 47: Kidney Cancer: Next Generation Diagnostic Tests, 2020
    • Table 48: Leukemia and Myeloma: Next Generation Diagnostic Tests, 2020
    • Table 49: Liver Cancer: Next Generation Diagnostic Tests, 2020
    • Table 50: Five-Year Survival Rates for Non-Small Cell Lung Cancer, 2020
    • Table 51: Lung Cancer: Next Generation Diagnostic Tests, 2020
    • Table 52: Lymphoma: Next Generation Diagnostic Tests, 2020
    • Table 53: Melanoma: Next Generation Diagnostic Tests, 2020
    • Table 54: Pan-Cancer: Next Generation Diagnostic Tests, 2020
    • Table 55: Prostate Cancer Next Generation Diagnostic Tests, 2020
    • Table 56: Thyroid Cancer: Next Generation Diagnostics Tests, 2020
    • Table 57: Advanced Sequencing Industry Company Positioning
    • Table 58: End-to-End Sequencing Approaches
    • Table 59: Long-Read Sequencing Industry
    • Table 60: Sequencing Informatics Industry
    • Table 61: PCR Companies
    • Table 62: Advantages of Droplet Digital PCR for Single-Cell Analysis
    • Table 63: Digital PCR Liquid Biopsy Industry
    • Table 64: CTC Separations Industry
    • Table 65: Liquid Biopsy Assay Industry: Company Focus
    • Table 66: NGS-Based Liquid Biopsy Market Differentiation
    • Table 67: Cancer Diagnostics Industry Acquisitions, Jan. 2019-July 2020
    • Table 68: Cancer Diagnostics Strategic Alliances, Jan. 2019-July 2020
    • Table 69: Liquid Biopsy: Forces Driving Growth, 2020
    • Table 70: Limitations of Solid Biopsy in Cancer Applications
    • Table 71: Low-Frequency Mutation Detection
    • Table 72: Global Market for Next Generation Cancer Diagnostics, by Cancer Site, Through 2025
    • Table 73: Ovarian Cancer: Five-Year Survival Rate
    • Table 74: NIH Liquid Biopsy Early Detection Initiative
    • Table 75: Global Market for Next Generation Cancer Diagnostics, by Purpose of Analysis, Through 2025
    • Table 76: MRI and Liquid Biopsy Methods
    • Table 77: Early Detection: Tissue of Origin Approaches
    • Table 78: Global Market for Next Generation Cancer Diagnostics, by Test Platform, Through 2025
    • Table 79: FDA-Approved or CE-Marked Tests with Epigenetic Component
    • Table 80: Global Market for PCR-Based Cancer Diagnostics, by Cancer Site, Through 2025
    • Table 81: Global Market for NGS-Based Cancer Diagnostics, by Cancer Site, Through 2025
    • Table 82: Global Market for Next Generation Cancer Screening/Early Detection, by Cancer Site, Through 2025
    • Table 83: Global Market for Next Generation Cancer Diagnosis, by Cancer Site, Through 2025
    • Table 84: Global Market for Next Generation Cancer Monitoring, by Cancer Site, Through 2025
    • Table 85: Global Market for Next Generation Cancer Therapy Guidance, by Cancer Site, Through 2025
    • Table 86: Global Market for Breast Cancer Diagnostics, by Analysis Method, Through 2025
    • Table 87: Global Market for Colorectal Cancer Diagnostics, by Analysis Method, Through 2025
    • Table 88: Global Market for Lung Cancer Diagnostics, by Analysis Method, Through 2025
    • Table 89: Global Market for Pan-Cancer Diagnostics, by Analysis Method, Through 2025
    • Table 90: Global Market for Prostate Cancer Diagnostics, by Analysis Method, Through 2025
    • Table 91: Global Market for Next Generation Cancer Diagnostics, by Region, Through 2025
    • Table 92: Patent Activity: Circulating Tumor Cells (CTCs), by Region, Jan. 2010-June 2020
    • Table 93: Patent Activity: Exosomes, by Region, Jan. 2010-June 2020
    • Table 94: Patent Activity: cfDNA, by Region, 2010-June 2020
    • Table 95: Patent Activity: Cancer Biomarkers, by Region, Jan. 2010-June 2020

List of Figures

  • Summary Figure: Global Market for Next Generation Cancer Diagnostics, by Cancer Site, 2019-2025